作者: K. Hull , I. Kerridge , S. Avery , M. McCullough , D. Ritchie
DOI: 10.1111/IMJ.12812
关键词: Hematopoietic stem cell transplantation 、 Graft-versus-host disease 、 Allogeneic hsct 、 Tacrolimus 、 Oral cavity 、 Medicine 、 Intensive care medicine 、 Disease 、 Quality of life 、 Surgery 、 Transplantation
摘要: Data from the Australasian Bone Marrow Transplant Recipient Registry show a steady increase in number of allogeneic haemopoietic stem cell transplantations (HSCT) performed annually Australia and New Zealand. In 2012, 629 HSCT were performed. Allogeneic is associated with numerous potential complications, including chronic graft-versus-host disease (cGVHD). The oral cavity one most frequent sites affected by cGvHD, often leading to significant disability reduced quality life. Management strategies are complex, variable efficacy influenced availability various therapeutic agents, access compounding pharmacies costs. This paper summarises current status Zealand focus on cGvHD challenges its management.